secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001689548-25-000094
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis reports RADIANT study positive: 56.3% median seizure reduction; Q2 net loss $71.1M
--------------------------------------------------------------------------------

- Vormatrigine in focal onset seizures (n=37): 56.3% median reduction in seizure frequency over 8 weeks; 22% achieved 100% reduction in last 28 days.
- Cash and investments $446.6M at June 30, 2025, providing runway into 2028.
- Q2 2025 net loss $71.1M vs $32.7M in Q2 2024; R&D expenses rose to $63.0M from $27.3M.
- Relutrigine received FDA Breakthrough Therapy Designation for SCN2A and SCN8A DEEs in July 2025.
- Initiated registrational studies: EMERALD (broad DEEs with relutrigine) and EMBRAVE3 (SCN2A GoF with elsunersen).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000094/0001689548-25-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000094/prax-20250804.htm
  HTML page:      https://secwatch.observer/filing/0001689548-25-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer